116 related articles for article (PubMed ID: 25141899)
1. Calcineurin inhibitors and hypertension: a role for pharmacogenetics?
Moes AD; Hesselink DA; Zietse R; van Schaik RH; van Gelder T; Hoorn EJ
Pharmacogenomics; 2014 Jun; 15(9):1243-51. PubMed ID: 25141899
[TBL] [Abstract][Full Text] [Related]
2. Biomarkers for individualized dosage adjustments in immunosuppressive therapy using calcineurin inhibitors after organ transplantation.
Fu R; Tajima S; Suetsugu K; Watanabe H; Egashira N; Masuda S
Acta Pharmacol Sin; 2019 Feb; 40(2):151-159. PubMed ID: 29950613
[TBL] [Abstract][Full Text] [Related]
3. Influence of CYP3A5 and ABCB1 gene polymorphisms on calcineurin inhibitor-related neurotoxicity after hematopoietic stem cell transplantation.
Yanagimachi M; Naruto T; Tanoshima R; Kato H; Yokosuka T; Kajiwara R; Fujii H; Tanaka F; Goto H; Yagihashi T; Kosaki K; Yokota S
Clin Transplant; 2010; 24(6):855-61. PubMed ID: 20030680
[TBL] [Abstract][Full Text] [Related]
4. The calcineurin inhibitor tacrolimus activates the renal sodium chloride cotransporter to cause hypertension.
Hoorn EJ; Walsh SB; McCormick JA; Fürstenberg A; Yang CL; Roeschel T; Paliege A; Howie AJ; Conley J; Bachmann S; Unwin RJ; Ellison DH
Nat Med; 2011 Oct; 17(10):1304-9. PubMed ID: 21963515
[TBL] [Abstract][Full Text] [Related]
5. Clinical implementation of pharmacogenetics in kidney transplantation: calcineurin inhibitors in the starting blocks.
Elens L; Bouamar R; Shuker N; Hesselink DA; van Gelder T; van Schaik RH
Br J Clin Pharmacol; 2014 Apr; 77(4):715-28. PubMed ID: 24118098
[TBL] [Abstract][Full Text] [Related]
6. From gut to kidney: transporting and metabolizing calcineurin-inhibitors in solid organ transplantation.
Knops N; Levtchenko E; van den Heuvel B; Kuypers D
Int J Pharm; 2013 Aug; 452(1-2):14-35. PubMed ID: 23711732
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics, Pharmacodynamics and Pharmacogenetics of Tacrolimus in Kidney Transplantation.
Yu M; Liu M; Zhang W; Ming Y
Curr Drug Metab; 2018; 19(6):513-522. PubMed ID: 29380698
[TBL] [Abstract][Full Text] [Related]
8. Pathophysiological mechanisms of calcineurin inhibitor-induced nephrotoxicity and arterial hypertension.
Hošková L; Málek I; Kopkan L; Kautzner J
Physiol Res; 2017 May; 66(2):167-180. PubMed ID: 27982677
[TBL] [Abstract][Full Text] [Related]
9. Genetic variance in ABCB1 and CYP3A5 does not contribute toward the development of chronic kidney disease after liver transplantation.
Tapirdamaz Ö; Hesselink DA; el Bouazzaoui S; Azimpour M; Hansen B; van der Laan LJ; Polak WG; Kwekkeboom J; van Schaik RH; van Gelder T; Metselaar HJ
Pharmacogenet Genomics; 2014 Sep; 24(9):427-35. PubMed ID: 25014506
[TBL] [Abstract][Full Text] [Related]
10. Pathophysiology of Post Transplant Hypertension in Kidney Transplant: Focus on Calcineurin Inhibitors Induced Oxidative Stress and Renal Sodium Retention and Implications with RhoA/Rho Kinase Pathway.
Calò LA; Ravarotto V; Simioni F; Naso E; Marchini F; Bonfante L; Furian L; Rigotti P
Kidney Blood Press Res; 2017; 42(4):676-685. PubMed ID: 29131070
[TBL] [Abstract][Full Text] [Related]
11. Understanding the genetic basis for adverse drug effects: the calcineurin inhibitors.
Bai JP; Lesko LJ; Burckart GJ
Pharmacotherapy; 2010 Feb; 30(2):195-209. PubMed ID: 20099993
[TBL] [Abstract][Full Text] [Related]
12. Calcineurin inhibitor sparing regimens using m-target of rapamycin inhibitors: an opportunity to improve cardiovascular risk following kidney transplantation?
Zeier M; Van Der Giet M
Transpl Int; 2011 Jan; 24(1):30-42. PubMed ID: 20642495
[TBL] [Abstract][Full Text] [Related]
13. Challenges in diagnosing acute calcineurin-inhibitor induced nephrotoxicity: from toxicogenomics to emerging biomarkers.
Pallet N; Djamali A; Legendre C
Pharmacol Res; 2011 Jul; 64(1):25-30. PubMed ID: 21473913
[TBL] [Abstract][Full Text] [Related]
14. NaCl cotransporter abundance in urinary vesicles is increased by calcineurin inhibitors and predicts thiazide sensitivity.
Tutakhel OAZ; Moes AD; Valdez-Flores MA; Kortenoeven MLA; Vrie MVD; Jeleń S; Fenton RA; Zietse R; Hoenderop JGJ; Hoorn EJ; Hilbrands L; Bindels RJM
PLoS One; 2017; 12(4):e0176220. PubMed ID: 28430812
[TBL] [Abstract][Full Text] [Related]
15. Conversion to everolimus in kidney transplant recipients: to believe or not believe?
Cotovio P; Neves M; Santos L; Macário F; Alves R; Mota A
Transplant Proc; 2012 Dec; 44(10):2966-70. PubMed ID: 23195007
[TBL] [Abstract][Full Text] [Related]
16. Pathogenesis of calcineurin inhibitor-induced hypertension.
Hoorn EJ; Walsh SB; McCormick JA; Zietse R; Unwin RJ; Ellison DH
J Nephrol; 2012; 25(3):269-75. PubMed ID: 22573529
[TBL] [Abstract][Full Text] [Related]
17. Steroid and calcineurin inhibitor-sparing protocols in kidney transplantation.
Helal I; Chan L
Transplant Proc; 2011 Mar; 43(2):472-7. PubMed ID: 21440737
[TBL] [Abstract][Full Text] [Related]
18. Association between CYP3A5 polymorphisms and blood pressure in kidney transplant recipients receiving calcineurin inhibitors.
Ferraresso M; Turolo S; Ghio L; Tirelli AS; Belingheri M; Villa R; Groppali E; Edefonti A
Clin Exp Hypertens; 2011; 33(6):359-65. PubMed ID: 21851254
[TBL] [Abstract][Full Text] [Related]
19. Calcineurin inhibitor nephrotoxicity: a review and perspective of the evidence.
Issa N; Kukla A; Ibrahim HN
Am J Nephrol; 2013; 37(6):602-12. PubMed ID: 23796509
[TBL] [Abstract][Full Text] [Related]
20. Calcineurin inhibitors in heart transplantation.
Keogh A
J Heart Lung Transplant; 2004 May; 23(5 Suppl):S202-6. PubMed ID: 15093806
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
